Stock Market News
Shire's angioedema treatment fast-tracked in EU and Canada
Shire has gained approval from the EU and Canada for accelerated assessments of its lanadelumab treatment for hereditary angioedema (HAE).
The European Medicines Agency has validated Shire's marketing authorisation application for lanadelumab and Health Canada has accepted a new drug submission under priority review for the treatment.
The EMA's validation means an accelerated assessment for the potential therapy can begin after the number of evaluation days required was reduced from 210 to 150 in January. Health Canada's acceptance of the treatment for priority review shortens the timeline from 300 days to 180 days.
HAE is a rare, genetic disorder that causes debilitating, painful and sometimes life-threatening swelling in the body. Lanadelumab is an antibody Shire is seeking to develop for the prevention of angioedema attacks in patients aged 12 and older with the HAE.
Shire, which this week has been subject of bid interest from Japan's Takeda Pharmaceutical, said lanadelumab's progress reinforced its leadership in rare disease treatments. Lanadelumab has also been given priority review status in the US and Australia.
Andreas Busch, Shire's head of research and development said: "HAE presents a significant burden on the lives of patients whose recurring attacks of swelling can be debilitating and painful. Lanadelumab is the first monoclonal antibody under evaluation to prevent HAE attacks and has the potential to change the treatment paradigm for this rare disease, if approved. We look forward to working with regulatory bodies to bring a new treatment option to HAE patients."
The European Medicines Agency has validated Shire's marketing authorisation application for lanadelumab and Health Canada has accepted a new drug submission under priority review for the treatment.
The EMA's validation means an accelerated assessment for the potential therapy can begin after the number of evaluation days required was reduced from 210 to 150 in January. Health Canada's acceptance of the treatment for priority review shortens the timeline from 300 days to 180 days.
HAE is a rare, genetic disorder that causes debilitating, painful and sometimes life-threatening swelling in the body. Lanadelumab is an antibody Shire is seeking to develop for the prevention of angioedema attacks in patients aged 12 and older with the HAE.
Shire, which this week has been subject of bid interest from Japan's Takeda Pharmaceutical, said lanadelumab's progress reinforced its leadership in rare disease treatments. Lanadelumab has also been given priority review status in the US and Australia.
Andreas Busch, Shire's head of research and development said: "HAE presents a significant burden on the lives of patients whose recurring attacks of swelling can be debilitating and painful. Lanadelumab is the first monoclonal antibody under evaluation to prevent HAE attacks and has the potential to change the treatment paradigm for this rare disease, if approved. We look forward to working with regulatory bodies to bring a new treatment option to HAE patients."
Related share prices |
---|
Shire Plc (SHP) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price